Compare IBRX & HLI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | IBRX | HLI |
|---|---|---|
| Founded | 2014 | 1972 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Investment Managers |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 8.2B | 9.7B |
| IPO Year | 2015 | 2015 |
| Metric | IBRX | HLI |
|---|---|---|
| Price | $7.63 | $128.99 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 7 | 7 |
| Target Price | $12.57 | ★ $194.29 |
| AVG Volume (30 Days) | ★ 8.5M | 951.0K |
| Earning Date | 05-08-2026 | 05-06-2026 |
| Dividend Yield | N/A | ★ 1.54% |
| EPS Growth | ★ 38.71 | 6.87 |
| EPS | N/A | ★ 1.15 |
| Revenue | $113,288,000.00 | ★ $2,617,516,000.00 |
| Revenue This Year | $88.59 | $13.77 |
| Revenue Next Year | $131.15 | $12.10 |
| P/E Ratio | ★ N/A | $112.22 |
| Revenue Growth | ★ 668.31 | 9.55 |
| 52 Week Low | $1.95 | $112.83 |
| 52 Week High | $12.43 | $211.78 |
| Indicator | IBRX | HLI |
|---|---|---|
| Relative Strength Index (RSI) | 49.70 | 47.00 |
| Support Level | $6.68 | $112.83 |
| Resistance Level | $8.46 | $144.92 |
| Average True Range (ATR) | 0.33 | 4.40 |
| MACD | 0.06 | 0.47 |
| Stochastic Oscillator | 58.28 | 58.31 |
ImmunityBio Inc is a biotechnology company focused on developing and commercializing next-generation immunotherapies designed to activate the patient's immune system and provide durable protection against cancer and infectious diseases. Its approach harnesses both the adaptive and innate immune systems with the Cancer BioShield platform. The platform is built around the proprietary IL-15 superagonist ANKTIVA (nogapendekin alfa inbakicept) and is supported by a portfolio that includes adenovirus-vectored vaccines, NK-cell therapies, and additional immunomodulators. The company operates in the United States and Europe, with the majority of its revenue coming from the United States.
Houlihan Lokey Inc is an investment bank with expertise in mergers and acquisitions, capital markets, financial restructuring, valuation, and strategic consulting. The firm serves corporations, institutions, and governments world-wide with offices in the United States, Europe, and the Asia-Pacific region. The company operates in three segments. In the Corporate Finance business segment, it provides M&A and capital markets advisory services. Through the Financial Restructuring business segment, the company advises on some of the complex restructurings around the world. The Financial and Valuation Advisory Services business segment provides valuation and financial opinion, and financial and strategic consulting practices in the United States.